Apr 15, 2016

Posted by in Biotech Stocks | 0 Comments

Sizzling News: Athersys Inc (NASDAQ:ATHX), Bio Marin Pharmaceutical Inc (NASDAQ:BMRN), Baxalta Inc (NYSE:BXLT)

Sizzling News: Athersys Inc (NASDAQ:ATHX), Bio Marin Pharmaceutical Inc (NASDAQ:BMRN), Baxalta Inc (NYSE:BXLT)

Athersys Inc (NASDAQ:ATHX) stock is at $2.49, up +5.06 percent from its previous close of $2.37. The stock opened the session at $2.39 and touched its highest price point at $2.52. The company’s stock’s lowest price point for the session stood at $2.30. Its yesterday’s volume was 1.30 million shares in comparison to its usual trading volume of 1.23 million shares.

Athersys Inc (NASDAQ:ATHX) on March 10, 2016 reported that for the three months ended December 31, 2015, total revenues were $10.6 million compared to $0.2 million in the same period in 2014, reflecting the recognition of the full $10 million license fee that we received in 2015 from Chugai upon the termination of the collaboration in October 2015 and an increase in grant revenue.

Research and development expenses decreased to $5.3 million in the fourth quarter of 2015 from $5.6 million in the 2014 fourth quarter, primarily due to reduced clinical and preclinical development costs, which vary based on trials underway and clinical manufacturing campaigns. General and administrative expenses were $1.8 million in the fourth quarter of 2015 compared to $1.6 million in the corresponding 2014 period, reflecting increases in legal and professional fees, personnel costs and stock-based compensation.

Bio Marin Pharmaceutical Inc (NASDAQ:BMRN) stock is at $88.85, up +0.37 percent from its previous close of $88.52. Its yesterday’s volume was 1.42 million shares in comparison to its usual trading volume of 1.68 million shares. Previous 5 days graph demonstrated a positive move of 1.21%. Its quarterly performance remained green with the percentage of 5.24, while its year to date performance showed that the stock plunged overall -16%.

Bio Marin Pharmaceutical Inc (NASDAQ:BMRN) announced on April 12, 2016, that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 28, at 4:30 p.m. ET to discuss first quarter 2016 financial results and provide a general business update.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; and Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.

Baxalta Inc (NYSE:BXLT) traded in the range of $40.74 and $41.29 in its previous trading session. The stock recorded the volume of 7.13 million shares so far, in comparison its average daily trading volume of 11.53 million shares. Company’s year to date performance remained quiet optimistic with the rise of 4.32%. The stock opened at $40.84 and its closing price for the day was $40.76, down -0.59 percent from its previous close.

Baxalta Inc (NYSE:BXLT) on April 4, 2016 announced that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment, for patients 12 years and older with hemophilia A.

ADYNOVATE is built on ADVATE [Antihemophilic Factor (Recombinant)], the world’s most widely used FVIII treatment for hemophilia A with more than 12 years of patient experience. ADYNOVATE leverages proprietary pegylation technology2 designed to extend the time FVIII is available in the body. The technology reduces the speed at which ADYNOVATE is cleared from the blood, resulting in increased circulating half-life.

Following approval from the Ministry of Health, Labour and Welfare on March 28, the marketing authorization was transferred from Baxter Limited to Baxalta Japan Limited. In the United States, ADYNOVATE is currently licensed for use in adult and adolescent patients (12 years and older) and is under regulatory review for use in pediatric and surgical settings. ADYNOVATE is also under regulatory review in Canada, Switzerland and Europe.



Comments are closed.